Investors of ImmunityBio, Inc. Urged to Participate in Class Action Regarding Securities Fraud
ImmunityBio, Inc. Class Action Lawsuit Overview
The Rosen Law Firm, a respected legal entity focusing on investor rights, has recently alerted shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) regarding an important class action lawsuit. For those who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, there's significant news about the potential for compensation related to alleged securities fraud. The deadline for filing as a lead plaintiff in this case is set for May 26, 2026.
What Does This Mean for Investors?
If you have experienced losses exceeding $100,000 through your investment in ImmunityBio during the specified class period, you could be eligible to take part in this class action lawsuit. The legal framework allows you to pursue compensation without facing out-of-pocket expenses through a contingency fee model.
Class Action Steps:
To become part of the ImmunityBio class action, investors can visit this link or directly contact Phillip Kim, Esq. via toll-free number 866-767-3653. Additionally, you can email inquiries to [email protected]. It’s important to note that a class action lawsuit is already in progress, emphasizing the urgency for potential lead plaintiffs to act promptly.
Why Choose Rosen Law Firm?
Rosen Law Firm has garnered a reputation for representing investors globally. Their specialty in securities class actions and shareholder derivative litigation has led them to achieve substantial settlements, with notable success in previous cases. In 2019, the firm secured upwards of $438 million for investors. They have been recognized for their legal prowess, most notably being ranked highly by ISS Securities Class Action Services.
Core Allegations
The lawsuit claims that, during the class period, ImmunityBio’s leadership made misleading statements regarding the capabilities of Anktiva, a drug which has been a focus of investor interest. Allegedly, false claims about its effectiveness and the company's operational status led to substantial losses for investors when the actual conditions were revealed.
Join the Class Action Today
If you're contemplating whether to participate, remember that until a class is certified, you are not represented unless you retain counsel. Investors are encouraged to evaluate potential legal representation. Your ability to obtain a recovery in any future settlement does not rely on being a lead plaintiff, meaning you can still join without having to take a leading role in the litigation.
Follow Us for Future Updates
Stay updated on this unfolding situation by following Rosen Law Firm’s social media channels on LinkedIn, Twitter, and Facebook.
Closing Thoughts
Investors of ImmunityBio have a critical opportunity to join in a class action aimed at addressing alleged securities fraud, with the deadline fast approaching. If you invested during the identified period and are experiencing significant losses, now is the time to act and secure your potential rights.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.